CoChat

Nuclear inclusion bodies of mutant and wild‐type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation

Open access
De Smet, Frederik, Saiz Rubio, Mirian, Hompes, Daphne, Naus, Evelyne, De Baets, Greet, Langenberg, Tobias, Hipp, Mark S, Houben, Bert, Claes, Filip, Charbonneau, Sarah, Delgado Blanco, Javier, Plaisance, Stephane, Ramkissoon, Shakti, Ramkissoon, Lori, Simons, Colinda, van den Brandt, Piet, Weijenberg, Matty, Van England, Manon, Lambrechts, Sandrina, Amant, Frederic, D'Hoore, André, Ligon, Keith L, Sagaert, Xavier, Schymkowitz, Joost, Rousseau, Frederic · 2017 · The Journal of Pathology
Cited by 70

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their impact in cancer remains largely unknown. Here, we extensively screened for p53 aggregation phenotypes in tumour biopsies, and identified nuclear inclusion bodies (nIBs) of transcriptionally inactive mutant or wild‐type p53 as the most frequent aggregation‐like phenotype across six different cancer types. p53‐positive nIBs co‐stained with nuclear aggregation markers, and shared molecular hallmarks of nIBs commonly found in neurodegenerative disorders. In cell culture, tumour‐associated stress was a strong inducer of p53 aggregation and nIB formation. This was most prominent for mutant p53, but could also be observed in wild‐type p53 cell lines, for which nIB formation correlated with the loss of p53's transcriptional activity. Importantly, protein aggregation also fuelled the dysregulation of the proteostasis network in the tumour cell by inducing a hyperactivated, oncogenic heat‐shock response, to which tumours are commonly addicted, and by overloading the proteasomal degradation system, an observation that was most pronounced for structurally destabilized mutant p53. Patients showing tumours with p53‐positive nIBs suffered from a poor clinical outcome, similar to those with loss of p53 expression, and tumour biopsies showed a differential proteostatic expression profile associated with p53‐positive nIBs. p53‐positive nIBs therefore highlight a malignant state of the tumour that results from the interplay between (1) the functional inactivation of p53 through mutation and/or aggregation, and (2) microenvironmental stress, a combination that catalyses proteostatic dysregulation. This study highlights several unexpected clinical, biological and therapeutically unexplored parallels between cancer and neurodegeneration. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/path.4872

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 70

Metadata

Authors
De Smet, F., Saiz Rubio, M., Hompes, D., Naus, E., De Baets, G., Langenberg, T., Hipp, M. S., Houben, B., Claes, F., Charbonneau, S., Delgado Blanco, J., Plaisance, S., Ramkissoon, S., Ramkissoon, L., Simons, C., van den Brandt, P., Weijenberg, M., Van England, M., Lambrechts, S., Amant, F., D'Hoore, A., Ligon, K. L., Sagaert, X., Schymkowitz, J., & Rousseau, F.
Venue
The Journal of Pathology
Publisher
Wiley
Published
2017-03-23
Volume
242
Issue
1
Pages
24-38
ISSN
  • 0022-3417 (ISSN-L)
  • 1096-9896
OpenAlex
W2562135394
Cited by
70
References
11
FWCI
2.63
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nuclear inclusion bodies of mutant and wild‐type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. https://app.cochat.ai/papers/10.1002/path.4872
The paper
De Smet, F., Saiz Rubio, M., Hompes, D., Naus, E., De Baets, G., Langenberg, T., Hipp, M. S., Houben, B., Claes, F., Charbonneau, S., Delgado Blanco, J., Plaisance, S., Ramkissoon, S., Ramkissoon, L., Simons, C., van den Brandt, P., Weijenberg, M., Van England, M., Lambrechts, S., . . . Rousseau, F. (2017). Nuclear inclusion bodies of mutant and wild‐type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. The Journal of Pathology. https://doi.org/10.1002/path.4872

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.